Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y. Kamatani N, et al. Among authors: matsuzawa y. J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S35-43. doi: 10.1097/RHU.0b013e31821d351d. J Clin Rheumatol. 2011. PMID: 21654268 Clinical Trial.
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y. Kamatani N, et al. Among authors: matsuzawa y. J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S13-8. doi: 10.1097/RHU.0b013e31821d36cc. J Clin Rheumatol. 2011. PMID: 21654265 Clinical Trial.
Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y. Kamatani N, et al. Among authors: matsuzawa y. J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S19-26. doi: 10.1097/RHU.0b013e31821d36de. J Clin Rheumatol. 2011. PMID: 21654266 Clinical Trial.
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y. Kamatani N, et al. Among authors: matsuzawa y. J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S44-9. doi: 10.1097/RHU.0b013e31821d352f. J Clin Rheumatol. 2011. PMID: 21654269 Clinical Trial.
Clinical significance of the estimation of pulmonary-right ventricular uncoupling in patients with transthyretin amyloid cardiomyopathy.
Usuku H, Yamamoto E, Miyazaki K, Higashi R, Nozuhara A, Oike F, Kuyama N, Tabata N, Ishii M, Hanatani S, Hoshiyama T, Kanazawa H, Sueta D, Arima Y, Oda S, Kawano H, Matsuzawa Y, Izumiya Y, Ueda M, Tanaka Y, Tsujita K. Usuku H, et al. Among authors: matsuzawa y. Eur Heart J Imaging Methods Pract. 2025 Jan 17;3(1):qyae113. doi: 10.1093/ehjimp/qyae113. eCollection 2025 Jan. Eur Heart J Imaging Methods Pract. 2025. PMID: 39831277 Free PMC article.
1,313 results